Celularity Announces Net Sales Expectations for First Quarter 2024 and Full Year 2024, Reiterates Advanced Biomaterial Product Commercial and Development Pipeline - Seite 2

“Our sales of advanced biomaterial products grew dramatically in the fourth quarter of 2023 as our newest Biovance 3L product gained traction. We hope to build on the net sales growth we observed in the fourth quarter 2023 and continue to grow net sales of our advanced biomaterial products in 2024, which if achieved would meaningfully increase cash provided by operations and move us toward our goal of becoming a cashflow positive enterprise,” said Robert J. Hariri, M.D., Ph.D., Chairman, Chief Executive Officer, and founder. “We believe Celularity is a novel pairing of commercial-stage, cashflow generating advanced biomaterial product and biobanking businesses and a clinical-stage cell therapy business, all enabled by a unique technology platform that combines cellular and regenerative medicine technologies,” Hariri noted. “We are optimistic about our unique business model and encouraged by the organic growth in revenues, which we intend to complement through expanding into new markets,” said Dr. Hariri, who added, “So far, we see January sales of our advanced biomaterial products trending above our expected net sales for the first quarter 2024. We are continuing to explore ways to leverage our unique technology platform, GMP manufacturing infrastructure, and intellectual property portfolio to attract even more commercial and development relationships that are accretive in the near and long-term.”

The Company in 2024 expects to continue to improve the operational effectiveness of its advanced biomaterial product business and to prepare for a possible second half 2024 commercial launch of a new product for wound care and surgical applications. In addition, the Company expects to pursue additional advanced biomaterial product contract manufacturing opportunities under which it provides product development and manufacturing services for a third party which then sells the product(s) under its own brand name(s). For example, in December 2023, the Company entered into a contract manufacturing arrangement with BioCellgraft Inc. (“BioCellgraft“) under which it agreed to manufacture multiple advanced biomaterial products for BioCellgraft that BioCellgraft will sell in the United States under its own brand names for use in various oral health applications. The Company expects in 2024 to continue to assess opportunities to sell its advanced biomaterial products outside the United States but has, at this time, not included any amount attributable to ex-US sales in expected first quarter 2024 or expected full year 2024 net sales.